Prime Therapeutics Rolls Out New Real Time Benefit Tool

With the deadline approaching for Medicare Part D plans to implement a Real Time Benefit Tool (RTBT) — which informs prescribers when lower-cost alternative therapies are available under a beneficiary’s drug benefit — one PBM is offering up a new tool to fulfill the requirement.

Prime Therapeutics, LLC, a PBM collectively owned by 18 Blue Cross and Blue Shield plans, said on Sept. 2 that it is rolling out a tool called Real Time Benefit Check, which works through the ePrescribe function of a health care provider’s electronic health record (EHR) system. The idea is to offer providers “comprehensive information so they can easily prescribe the most appropriate and cost-effective medications at the point of care,” per a news release from the PBM.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-Merck-COVID-19-Drug-Could-Gain-Emergency-Use-Authorization.jpg
October 14

Merck COVID-19 Drug Could Gain Emergency Use Authorization

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-More-MA-PD-PDP-Members-Will-Be-in-4-Star-Plans-in-2022.jpg
October 14

More MA-PD, PDP Members Will Be in 4-Star Plans in 2022

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-PhRMA-Blasts-Poll-About-Govt-Drug-Price-Negotiation-Support.jpg
October 14

PhRMA Blasts Poll About Gov’t Drug Price Negotiation Support

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today